Encouraging outcome from the 1H20 results. Margin from Analytica will continue to improve as their newer testings achieves process improvement. Analytica has also grown by 20% pcp. I'm continually impressed by their Analytica business and it proves that it is the crown jewel of the group.

Their software solutions is also growing strongly, although it is very small at the moment at ~$1-1.5m FY20 rev.

They have also said acquisitions are on the horizon.

FY20 forecast of ~$7m EBITDA, unclear if this is pre-AASB16 or post-it, but in any case it is encouraging.